Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 360 entries
View as:

A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00908908 Org: User:
Start: 03/31/09 End: 05/31/11 Due: 05/31/12

Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.

Phase: N/A Priority: Normal
NCT ID: NCT01437384 Org: User:
Start: 09/30/11 End: - Due: -

A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT00260065 Org: User:
Start: 05/31/05 End: 12/31/08 Due: 12/31/09

A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00165802 Org: User:
Start: 05/31/06 End: 01/31/09 Due: 01/31/10

An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01136967 Org: User:
Start: 08/31/10 End: 11/30/14 Due: 11/30/15

Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia

Phase: N/A Priority: Normal
NCT ID: NCT03001557 Org: User:
Start: 12/20/16 End: 04/17/20 Due: 04/17/21

A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms

Phase: N/A Priority: Normal
NCT ID: NCT01286194 Org: User:
Start: 04/30/06 End: 01/31/07 Due: 01/31/08

A Food-Effect Study of E7386 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03996226 Org: User:
Start: 06/07/19 End: 10/29/19 Due: 10/29/20

Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03250676 Org: User:
Start: 08/23/17 End: 10/26/23 Due: 10/26/24

A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01871727 Org: User:
Start: 05/30/13 End: 12/14/21 Due: 12/14/22

A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT04572243 Org: User:
Start: 09/23/20 End: 08/15/24 Due: 08/15/25

E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01133977 Org: User:
Start: 04/30/10 End: 11/30/14 Due: 11/30/15

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

Phase: N/A Priority: Normal
NCT ID: NCT04468659 Org: User:
Start: 07/14/20 End: 01/16/31 Due: 01/16/32

A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03627936 Org: User:
Start: 08/07/18 End: 09/02/18 Due: 09/02/19

Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01127178 Org: User:
Start: 03/29/10 End: 02/24/11 Due: 02/24/12

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT00548587 Org: User:
Start: 10/31/07 End: 08/31/09 Due: 08/31/10

A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)

Phase: N/A Priority: Normal
NCT ID: NCT01054456 Org: User:
Start: 10/27/09 End: 12/08/10 Due: 12/08/11

A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Phase: N/A Priority: Normal
NCT ID: NCT00360412 Org: User:
Start: 10/31/06 End: 04/30/08 Due: 04/30/09

Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)

Phase: N/A Priority: Normal
NCT ID: NCT00967499 Org: User:
Start: 07/13/09 End: 12/18/09 Due: 12/18/10

A Study to Assess the Safety and Tolerability of E2730 After Multiple Dose and the Food Effect After Single Dose in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04676685 Org: User:
Start: 12/16/20 End: 06/23/21 Due: 06/23/22

Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures

Phase: N/A Priority: Normal
NCT ID: NCT00914927 Org: User:
Start: 05/31/09 End: 12/21/11 Due: 12/21/12

Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00100932 Org: User:
Start: 12/31/04 End: - Due: -

To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures

Phase: N/A Priority: Normal
NCT ID: NCT02220972 Org: User:
Start: 03/31/15 End: 08/31/16 Due: 08/31/17

A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users

Phase: N/A Priority: Normal
NCT ID: NCT03158025 Org: User:
Start: 04/19/17 End: 07/04/18 Due: 07/04/19

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00050973 Org: User:
Start: - End: 03/31/05 Due: 03/31/06